Table 2 Dichotomous Scoring Used Across Antibodies for PD-L1 IHC Tests in Lung Cancer

22C3 (Dako) [pembrolizumab]

1% (used in training group): 1 study [4]^a

50% (determined as optimal cutoff): 1 study [4]^a

28–8 (Dako) [nivolumab]

1%: 3 studies [7, 10, 12]^a

5%: 2 studies [10, 11]^a

10%: 1 study [10]^a

50%: 1 study [11]^a

SP263 (Roche) [durvalumab]

25%: 3 studies [7, 14, 28]^a,b

SP142 (Roche) [atezolizumab]

1%: 2 studies [19, 20]^a

5%: 2 studies [19, 20]^a,c

50%: 1 study [20]^a

E1L3N (Cell Signaling Technology; reagent provider) [not applicable]

1%: 2 studies [20, 21]^a

5%: 4 studies [11, 20, 21, 23]^a,c

50%: 3 studies [11, 20, 21]^a